Shanghai Mental Health Center
Shanghai, Shanghai, Shanghai, China, 200000, 200030, China
NCT Number: NCT07479771
Targeted temporal interference stimulation (tTIS) of the caudate nucleus can modulate the abnormal electrophysiological activity in individuals with methamphetamine use disorder (MUD), thereby improving their impaired reward-learning behaviors and reducing drug craving.
This study is active but is not currently recruiting participants.
18 year–55 year
All sexes
Interventional
Not applicable
Shanghai, Shanghai, Shanghai, China, 200000, 200030, China
This project will recruit MUD patients. A 5-day intervention protocol of real or sham tTIS targeting the caudate nucleus will be employed. Before and after intervention, drug craving anddrug use and other questionnaire as well as stop-signal tasks, and reward-learning tasks will be used to evaluate its therapeutic efficacy on clinical craving and the underlying neural mechanisms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The stimulation duration are 30 minutes per session, administered twice daily for 5 consecutive days.
The stimulation parameters-including frequency, current intensity, and duration-are identical to those in the active group. However, the sham stimulation mode is activated on the device, resulting in no actual current being delivered during the stimulation.
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
Visual Analog Scale, range0-100 point. the higher the score, the more one wants drugs.
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
OCDUSE scale
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
This study employed the BIS-11 Impulsiveness Scale
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
the Impulsive-Control Dual Systems Scale
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
Stop Single Task
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
Reward LearningTask
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
delay discounting task
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
the Sensitivity to Punishment and Sensitivity to Reward Questionnaire, the Cognitive Flexibility Scale, the Behavioral Inhibition/Activation System Scale
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
the BDI Depression Inventory
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
the BAI Anxiety Inventory
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment
the PSQI Sleep Quality Index
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment
source power of each frequency band
Time frame: baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment
change of functional connection of brain area
Shanghai Mental Health Center
Other
Transcranial Temporal Interference Stimulation Targeted of the Striatum as an Intervention for Methamphetamine Use Disorder Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06454474
Amphetamine Use Disorders
Shanghai, Shanghai, Shanghai, China, 200000, China
View Trial DetailsNCT06165198
Amphetamine Use Disorders
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06960265
Amphetamine Abuse, Amphetamine Dependence
Nantou City, Taiwan
View Trial DetailsNCT03922646
Amphetamine Use Disorders, Behavior
Tulsa, Oklahoma, United States
View Trial Details